...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The Canadian journal of hospital pharmacy. >Ticagrelor and Acetylsalicylic Acid after Placement of Pipeline Embolization Device for Cerebral Aneurysm: A Case Series
【24h】

Ticagrelor and Acetylsalicylic Acid after Placement of Pipeline Embolization Device for Cerebral Aneurysm: A Case Series

机译：在脑动脉瘤管道栓塞装置放置后TiCagreloLor和乙酰胱氨酸：一个案例系列

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background: Dual antiplatelet therapy with acetylsalicylic acid (ASA) and a P2Y12-receptor antagonist is often used to prevent thrombotic complications after placement of a Pipeline embolization device (PED) for cerebral aneurysm. Although clopidogrel is common in this setting, high rates of nonresponse to this drug have made ticagrelor a potentially attractive alternative.Objective: To describe safety and efficacy outcomes for ticagrelor following PED placement, including measurement of platelet function.Methods: A retrospective analysis of data was completed for patients who underwent PED placement for cerebral aneurysm at a single centre between November 2015 and March 2017, with subsequent prescription of ticagrelor and ASA as dual antiplatelet therapy. The primary end point was any ischemic stroke or death within 1 year after the procedure. Intracranial hemorrhage was a secondary end point. Additionally, measurement of and values for platelet reactivity units (PRUs) during receipt of ticagrelor and ASA were evaluated.Results: A total of 29 patients were included in this retrospective study. One patient experienced ischemic stroke 226 days after placement of the PED. In addition, 3 patients died during the 1-year follow-up period for causes unrelated to stroke or bleeding complications. No cases of intracranial hemorrhage were observed. Samples for measurement of P2Y12 levels were drawn at the discretion of the neurointerventionalists, and the PRU value was measured at least once for 28 (97%) of the 29 patients. The mean number of PRU measurements per patient after initiation of ticagrelor was 2.1 (standard deviation [SD] 1). Mean PRU value after initiation of ticagrelor was 65 (SD 57).Conclusions: In this case series describing the use of ticagrelor and ASA as dual antiplatelet therapy after PED placement for cerebral aneurysm, there was just one ischemic stroke, which occurred after the dual antiplatelet therapy had been discontinued. Further prospective trials are needed to describe the utility of ticagrelor use after PED placement, as well as its dosing and monitoring.
机译：背景：用乙酰胱氨酸（ASA）和P2Y12-受体拮抗剂的双抗血小板治疗通常用于预防脑动脉瘤的管道栓塞装置（PED）后预防血栓形成并发症。虽然Clopidogrel在这种环境中常见，但这种药物的高速率已经使TiCagreloR成为一个潜在有吸引力的替代品。目的：为了描述PED放置后的TiCagreloR的安全性和功效结果，包括血小板函数的测量。方法：数据的回顾性分析为2015年11月至2017年11月至2017年3月间在单一中心进行脑动脉瘤的患者完成，随后用TicagreloLor和ASA作为双抗血小板治疗。主要终点是手术后1年内的任何缺血性卒中或死亡。颅内出血是次要终点。另外，评估血小板反应性单位（Prus）的测量值和血小板反应性单位（Prus）的值进行了评估。结果：在这项回顾性研究中共有29名患者。一名患者在放置PED后226天经历了缺血性卒中。此外，3名患者在1年的后续期间死于与中风或出血并发症无关的原因。没有观察到颅内出血的病例。为测量P2Y12水平的样品被神经诊断主义者判断，并且PRU值至少测量29例患者的28例（97％）。在发起Ticagreler后，每位患者的平均PRU测量的平均数量为2.1（标准偏差[SD] 1）。在TiCagreleler开始后的平均值为65（SD 57）。结论：在本案例中，描述使用TicagreloLor和ASA作为双抗血小板治疗后的脑动脉瘤后的双抗血小板治疗，只有一个缺血性卒中，在双重后发生抗血小板治疗已停止。需要进一步的前瞻性试验来描述PED放置后的TicagreloRoR使用的效用，以及其给药和监测。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号